Cyclosporin H is a potent and selective competitive antagonist of human basophil activation by N-formyl-methionylleucyl-phenylalanine

Journal of Allergy and Clinical Immunology

Volumn 98, Issue 1, 1996, Pages 152-164

  De Paulis, Amato ^a   Ciccarelli, Anna ^a   De Crescenzo, Gennaro ^a   Cirillo, Raffaele ^a   Patella, Vincenzo ^a   Marone, Gianni ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Basophils; Cyclophilin; Cyclosporin A; Cyclosporin H; Histamine; Leukotriene C4

Indexed keywords

CYCLOPHILIN; CYCLOSPORIN A; CYCLOSPORIN H; FORMYLMETHIONYLLEUCYLPHENYLALANINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE; INTERLEUKIN 1BETA; LEUKOTRIENE C4;

ADULT; ARTICLE; BASOPHIL; HISTAMINE RELEASE; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL;

BASOPHILS; BINDING, COMPETITIVE; CHEMOKINE CCL2; COMPLEMENT C5A; CYCLOSPORINE; HISTAMINE RELEASE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-8; KINETICS; LACTONES; LEUKOTRIENE C4; MACROLIDES; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; OLIGOPEPTIDES; PLATELET ACTIVATING FACTOR; PROTEIN BINDING; RANTES; TETRADECANOYLPHORBOL ACETATE;

EID: 0029776477     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(96)70237-3     Document Type: Article

References (67)

1. Dvorak AM, Mihm MC Jr, Dvorak HF. Degranulation of basophilic leukocytes in allergic contact dermatitis reactions in man. J Immunol 1976;116:687-95.
2. Koshino T, Teshima S, Fukushima N, et al. Identification of basophils by immunochemistry in the airways of post-mortem cases of fatal asthma. Clin Exp Allergy 1993;23:919-25.
3. Bochner BS, Undem BJ, Lichtenstein LM. Immunological aspects of allergic asthma. Annu Rev Immunol 1994;12:295-335.
4. Colvin RB, Dvorak HF. Basophils and mast cells in renal allograft rejection. Lancet 1974;1:212-4.
5. Dvorak AM, Monahan RA, Osage JE, Dickersin GR. Crohn's disease: transmission electron microscopic studies. II. Immunologic inflammatory response. Alterations of mast cells, basophils, eosinophils, and the microvasculature. Human Pathol 1980;11:606-19.
6. Valent P, Bettelheim P. Cell surface structures on human basophils and mast cells: biochemical and functional characterization. Adv Immunol 1992;52:333-423.
7. MacGlashan DW Jr. Signal transduction and cytokine production by human basophils. In: Marone G, ed. Human basophils and mast cells: biological aspects. Basel: Karger AG, 1995:88-113.
8. MacGlashan DW Jr, White JM, Huang S-K, Ono SJ, Schroeder JT, Lichtenstein LM. Secretion of IL-4 from human basophils: the relationship between IL-4 mRNA and protein in resting and stimulated basophils. J Immunol 1994;152:3006-16.
9. Gauchat J-F, Henchoz S, Mazzei G, et al. Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 1993;365:340-3.
10. Marone G. The role of basophils and mast cells in the pathogenesis of pulmonary diseases. Int Arch Allergy Appl Immunol 76(suppl 1):70-82.
11. Casolaro V, Galeone D, Giacummo A, Sanduzzi A, Melillo G, Marone G. Human basophil/mast cell releasability. V. Functional comparisons of cells obtained from peripheral blood, lung parenchyma and from bronchoalveolar lavage in asthmatics. Am Rev Respir Dis 1989;139:1375-82.
12. Marone G, Giugliano R, Lembo G, Ayala F. Human basophil releasability. II. Changes in basophil releasability in patients with atopic dermatitis. J Invest Dermatol 1986;87:19-23.
13. de Paulis A, Valentini G, Spadaro G, Lupoli S, Tirri G, Marone G. Human basophil releasability. VIII. Increased basophil releasability in patients with scleroderma. Arthritis Rheum 1991;34:1289-96.
14. Patella V, Marinò I, Lampärter B, Arbustini E, Adt M, Marone G. Human heart mast cells: isolation, purification, ultrastructure, and immunologic characterization. J Immunol 1995;154:2855-65.
15. Marone G, Kagey-Sobotka A, Lichtenstein LM. Effects of arachidonic acid and its metabolites on antigen-induced histamine release from human basophils in vitro. J Immunol 1979;123:1669-77.
16. Marone G, Tamburini M, Giudizi MG, Biagiotti R, Almerigogna F, Romagnani S. Mechanism of activation of human basophils by Staphylococcus aureus Cowan I. Infect Immun 1987;55:803-9.
17. Patella V, Casolaro V, Björck L, Marone G. Protein L: a bacterial Ig-binding protein that activates human basophils and mast cells. J Immunol 1990;145:3054-61.
18. Marone G, Casolaro V, Paganelli R, Quinti I. IgG anti-IgE from atopic dermatitis induces mediator release from basophils and mast cells. J Invest Dermatol 1989;93:246-52.
19. Hide M, Francis DM, Grattan CEH, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993;328:1599-604.
20. Marone G, Poto S, Columbo M, Giugliano R, Genovese A, Condorelli M. Possible role of calmodulin in the control of lysosomal enzyme release from human polymorphonuclear leukocytes. J Pharmacol Exp Ther 1984;231:678-84.
21. Siraganian RP, Hook WA. Mechanism of histamine release by formyl methionine-containing peptides. J Immunol 1977;119:2078-83.
22. Siraganian RP, Hook WA. Complement-induced histamine release from human basophils. II. Mechanism of the histamine release reaction. J Immunol 1976;116:639-46.
23. Casolaro V, Meliota S, Marino O, et al. Nimesulide, a sulfonanilide nonsteroidal anti-inflammatory drug, inhibits mediator release from human basophils and mast cells. J Pharmacol Exp Ther 1993;267:1375-85.
24. Alam R, Lett-Brown MA, Forsythe PA, et al. Monocyte chemotactic and activating factor is a potent histamine-releasing factor for basophils. J Clin Invest 1992;89:723-8.
25. Kuna P, Reddigari SR, Schall TJ, Rucinski D, Viksman MY, Kaplan AP. RANTES, a monocyte and T lymphocyte chemotactic cytokine releases histamine from human basophils. J Immunol 1992;149:636-42.
26. Krieger M, Brunner T, Bischoff SC, et al. Activation of human basophils through the IL-8 receptor. J Immunol 1992;149:2662-7.
27. Columbo M, Casolaro V, Warner JA, MacGlashan DW Jr, Kagey-Sobotka A, Lichtenstein LM. The mechanism of mediator release from human basophils induced by platelet-activating factor. J Immunol 1990;145:3855-61.
28. Murphy PM, Özcelik T, Kenney RT, Tiffany HL, McDermott D, Francke U. A structural homologue of the N-formyl peptide receptor: characterization and chromosome mapping of the peptide chemoattractant receptor family. J Biol Chem 1992;267:7637-43.
29. Marasco WA, Phan SH, Krutzsch H, et al. Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. J Biol Chem 1984;259:5430-9.
30. Rot A, Henderson LE, Copeland TD, Leonard EJ. A series of six ligands for the human formyl peptide receptor: tetrapeptides with high chemotactic potency and efficacy. Proc Natl Acad Sci 1987;84:7967-71.
31. Carp H. Mitochondrial N-formylmethionyl proteins as chemoattractants for neutrophils. J Exp Med 1982;155:264-75.
32. Knol EF, Koenderman L, Mul FPJ, Verhoeven AJ, Roos D. Differential activation of human basophils by anti-IgE and formyl-methionyl-leucyl-phenylalanine: indications for protein kinase C-dependent and -independent activation pathways. Eur J Immunol 1991;21:881-5.
33. Farnam J, Grant JA, Lett-Brown MA, Hunt C, Thueson DO, Giclas PC. Complement- and IgE-mediated release of histamine from basophils in vitro. V. Differential effects of drugs modulating arachidonic acid metabolism. J Immunol 1985;134:541-7.
34. Borel JF. The history of cyclosporin A and its significance. In: White DJG, ed. Cyclosporine A, Proceedings of an International Conference on Cyclosporine. New York: Elsevier Biomedical, 1982:5-17.
35. 4 from human lung mast cells. Ric Clin Lab 1988;18:53-9.
36. Cirillo R, Triggiani M, Siri L, et al. Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin. J Immunol 1990;144:3891-7.
37. Casolaro V, Spadaro G, Patella V, Marone G. In vivo characterization of the anti-inflammatory effect of cyclosporin A on human basophils. J Immunol 1993;151:5563-73.
38. + cells. J Immunol 1991;146:2374-81.
39. Liu J. FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. TiPS 1993;14:182-8.
40. Von Wartburg A, Traber R. Chemistry of the natural cyclosporin metabolites. Prog Allergy 1986;38:28-35.
41. Handschumacher RE, Harding MW, Rice J, Gruggs RJ, Speicher DW. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 1984;226:544-7.
42. LeGrue SJ, Turner R, Weisbrodt N, Dedman JR. Does the binding of Cyclosporine to calmodulin result in immunosuppression? Science 1986;234:68-71.
43. Gelfand, EW, Cheung RK, Mills GB. The cyclosporins inhibit lymphocyte activation at more than one site. J Immunol 1987;138:1115-20.
44. Benson A, Ziegler HF. Macrophages as targets for inhibition by Cyclosporine. Transplantation 1989;47:696-704.
45. Stellato C, de Paulis A, Ciccarelli A, et al. Anti-inflammatory effect of cyclosporin A on human skin mast cells. J Invest Dermatol 1992;98:800-4.
46. DeBoer M, Roos D. Metabolic comparisons between basophils and other leukocytes from human blood. J Immunol 1986;136:3447-54.
47. Gilbert HS, Ornstein L. Basophil counting with a new method using Alcian blue. Blood 1975;46:279-86.
48. Siraganian RP. An automated continuous-flow system for the extraction and fluorometric analysis of histamine. Anal Biochem 1974;57:383-94.
49. Marone G, Columbo M, Triggiani M, Cirillo R, Genovese A, Formisano S. Inhibition of IgE-mediated histamine and peptide leukotriene release from human basophils and mast cells by forskolin. Biochem Pharmacol 1987;36:13-20.
50. Naccache PH, Molski TFP, Volpi M, Mackin WM, Becker EL, Sha'afi RI. Inhibition of chemotactic factor-induced neutrophil responsiveness by arachidonic acid. J Cell Physiol 1983;115:243-8.
51. Snedecor GW, Cochran WG. Statistical methods. Ames, Iowa: The Iowa State University Press, 1980.
52. Schleimer RP, Gillespie E, Lichtenstein LM. Release of histamine from human leukocytes stimulated with the tumor-promoting phorbol diesters. I. Characterization of the response. J Immunol 1981;126:570-4.
53. Patella V, Casolaro V, Ciccarelli A, Pettit GR, Columbo M, Marone G. The antineoplastic bryostatins affect differently human basophils and mast cells. Blood 1995;85:1272-81.
54. Mohr H, Pettit GR, Plessing-Menze A. Co-induction of lymphokine synthesis by the antineoplastic bryostatins. Immunobiology 1987;175:420-30.
55. Warner, JA, Peters SP, Lichtenstein LM, et al. Differential release of mediators from human basophils: differences in arachidonic acid metabolism following activation by unrelated stimuli. J Leukoc Biol 1988;45:558-71.
56. Samuelsson B, Dahlén S-E, Lindgren JA, Rouzer CA, Serhan CH. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987;237:1171-6.
57. Marone G, Giordano A, Cirillo R, Triggiani M, Vigorito C. Cardiovascular and metabolic effects of peptide leukotrienes in man. Ann N Y Acad Sci 1988;524:321-3.
58. Undem BJ, Peachell PT, Lichtenstein LM. Isoproterenol-induced inhibition of immunoglobulin E-mediated release of histamine and arachidonic acid metabolites from the human lung mast cell. J Pharmacol Exp Ther 1988;247:209-17.
59. Marone G, Columbo M, Soppelsa L, Condorelli M. The mechanism of basophil histamine release induced by pepstatin A. J Immunol 1984;133:1542-6.
60. Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists. Br J Pharmacol 1959;14:48-55.
61. Lopez AF, Lyons AB, Eglinton JM, et al. Specific binding of human interleukin-3 and granulocyte-macrophage colony-stimulating factor to human basophils. J Allergy Clin Immunol 1990;85:99-102.
62. Valent P. Immunophenotypic characterization of human basophils and mast cells. In: Marone G, ed. Human basophils and mast cells: biological aspects. Basel: Karger AG, 1995:38-48.
63. + cells. In: Romagnani S, Abbas AK, eds. Cytokines: basic principles and clinical applications. New York: Raven Press, 1990;68:351-6.
64. Quiesniaux VFJ, Schreier MH, Wenger RM, Hiestand PC, Harding MW, Van Regenmortel MHV. Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive activity. Eur J Immunol 1987;17:1359-65.
65. Wenzel-Seifert K, Grunbaum L, Seifert R. Differential inhibition of human neutrophil activation by cyclosporins A, D, and H. Cyclosporin H is a potent and effective inhibitor of formyl peptide-induced Superoxide formation. J Immunol 1991;147:1940-6.
66. Wenzel-Seifert K, Seifert R. Cyclosporin H is a potent and selective formyl peptide receptor antagonist. Comparison with N-t-butoxycarbonyl-1-phenylalanyl-1-leucyl-1-phenylalanyl-1-leucyl-1- phenylalanine and cyclosporins A, B, C, D, and E. J Immunol 1993;150:4591-9.
67. Weisbart RH, Golde DW, Gasson JC. Biosynthetic human GM-CSF modulates the number and affinity of neutrophil f-Met-Leu-Phe receptors. J Immunol 1986;137:3584-7.